Concomitant radiotherapy with temozolomide significantly improves PFS in IDH-wildtype glioblastoma patients compared to radiotherapy alone. The study involved 244 patients, with 72.5% receiving ...

Disrupted brain fluid clearance in the hemisphere opposite the tumor emerges as a strong independent predictor of survival in patients with IDH wild-type glioblastoma. Glioblastoma—the most aggressive ...

Clinicopathologic and Molecular Analysis of Normal Karyotype Therapy-Related and De Novo Acute Myeloid Leukemia: A Multi-Institutional Study by the Bone Marrow Pathology Group The Lynch syndrome ...

Myosin Therapeutics Inc. has obtained IND clearance by the FDA for MT-125. A phase I study will evaluate MT-125 in combination with standard-of-care radiation in patients with newly diagnosed IDH wild ...

The findings include the identification of a 12-gene signature that could be used to categorize patients as high or low risk. GBM is the most common primary brain cancer in adults, and it is also one ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Now, patients are really divided since 2021 ...

Erdafitinib showed a predictable toxicity profile and early efficacy in IDH–wild-type glioma with FGFR-TACC fusions. The recommended phase 2 dose was 8 mg daily, with one grade 3 central serous ...